Institute Of Tropical Medicine

What Institute Of Tropical Medicine does

The Institute of Tropical Medicine (ITM), legally "Institute of Tropical Medicine" and operating as ITG/IMT/ITM, is a private, non-profit foundation of public utility founded in 1906 and headquartered at Nationalestraat 155, Antwerp, Belgium. It functions as a tripartite institution combining (i) advanced postgraduate education — master's programmes, postgraduate certificates, and short courses in tropical medicine, international public health, and Global One Health; (ii) specialized clinical services delivered through an Antwerp outpatient clinic that sees approximately 24,000 travelers annually, an HIV/AIDS and STI unit, a PrEP service, and the newly launched Chemsex Centre; and (iii) translational research and clinical trials on tropical and infectious diseases, supported by BSL-3 laboratory infrastructure and reference laboratories. Its revenue base draws from Belgian healthcare reimbursement for clinical services, tuition and training fees, and a diversified portfolio of competitive research grants and philanthropic donations, channeled through the Healthropist campaign and partners including CEPI, DGD, FWO, Horizon Europe, and the GHIT Fund.

The institute's core technology stack centers on a high-security BSL-3 laboratory and reference laboratory diagnostics for tropical pathogens, combined with adaptive clinical trial infrastructure. ITM coordinates and co-develops studies such as EBO-BOOST (mix-and-match Ebola booster vaccination, 624 participants), the WHO-sponsored PARTNERS adaptive platform trial for Bundibugyo Ebola treatments (MBP134 and remdesivir, up to 1,000 participants), IMPACT (orthopoxvirus antibody countermeasure development), MBOTE (mpox vaccine effectiveness in high-risk groups in DRC), and be-IMPACT (drug-resistant malaria surveillance across seven Belgian hospitals). It also develops digital patient-facing tools, notably the Wanda mobile application that delivers destination-specific travel health guidance. Distribution is delivered directly through the Antwerp clinic, in-person and online academic programmes, and field-based clinical trial sites in DRC (Kinshasa, Goma), Ghana, and other partner countries.

ITM serves a heterogeneous mix of customers: individual patients and travelers (clinic and Wanda), postgraduate professionals worldwide (education), and institutional research partners including WHO, Africa CDC, MSF, ALIMA, the University of Oxford, INRB, and pharmaceutical donors such as Gilead and Mapp Biopharmaceutical. It has been a WHO collaborating centre since its co-discovery of the Ebola virus in 1976 alongside Jean-Jacques Muyembe, and is currently marking its 120th anniversary in 2026 with the ITG Colloquium in Addis Ababa. The Wanda app is its sole consumer-facing software product; there is no public API, SDK or disclosed AI product surface.

Name

Institute Of Tropical Medicine

Legal name

Institute of Tropical Medicine

Website

https://itg.be

Company type

Private

Founded year

1906

Operating status

Operating

Short description

The Institute of Tropical Medicine (ITM) is a 120-year-old Antwerp-based non-profit foundation that delivers postgraduate education, specialized clinical services, and translational research in tropical and infectious diseases, serving patients, global health professionals, and institutional partners including WHO and Africa CDC.

Ownership category

akta.pro rank

Headquarters

HQ city

Antwerp

HQ country

Belgium

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Clinical Services: Revenue from outpatient clinic consultations for HIV/AIDS, STIs, travel medicine, and tropical diseases. The clinic serves approximately 24,000 travelers annually.
2. Education and Training Programs: Master's programmes, postgraduate certificate programmes, and expert short courses in tropical medicine, international public health, and Global One Health for professionals worldwide.
3. Research Grants and Donations: Funding from government agencies (CEPI, DGD, FWO), foundations, and philanthropic donations through Healthropist campaign.
4. Clinical Trial Services: Revenue from conducting clinical trials for pharmaceutical companies and international health organizations, including Ebola vaccine and treatment studies.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

The Institute of Tropical Medicine (ITM) is a non-profit research, postgraduate education, and specialized clinical care institution focused on tropical and infectious diseases. It runs Master's and postgraduate certificate programmes in tropical medicine and global health, operates an outpatient clinic delivering HIV/AIDS/STI care, PrEP services, chemsex support, and travel medicine consultations, and conducts clinical trials and reference-laboratory diagnostics in partnership with global health organizations and African, Asian, and Latin American institutions.

Product overview

ITM offers a comprehensive portfolio of research, clinical services, and education focused on tropical diseases, HIV/AIDS, tuberculosis, and infectious diseases. The core clinical services include an outpatient clinic specializing in HIV/AIDS and STIs, a travel clinic serving approximately 24,000 travelers annually, and specialized services including the Chemsex Centre. Research capabilities span clinical studies including EBO-BOOST (Ebola booster vaccines), PARTNERS Trial (Bundibugyo virus), IMPACT Project (orthopoxvirus antibodies), MBOTE (mpox vaccine evaluation in DRC), and Be-IMPACT (malaria monitoring). The Wanda mobile app provides travelers with destination-specific health guidance. Educational offerings include master's programmes, postgraduate certificates, and expert short courses in tropical medicine, international public health, and Global One Health. Supporting infrastructure includes reference laboratories, clinical trial facilities, and specialized research units in Clinical Immunology, Tropical Laboratory Medicine, and Clinical Tropical Medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Wanda App: Mobile application for travel health guidance, helping travelers check vaccination and medication requirements for destinations.

Products and services

• Wanda Travel Health App Mobile application that helps travelers check which vaccinations, medications and precautions are needed for each destination, reducing health risks during travel.
• HIV PrEP Service Pre-exposure prophylaxis service providing HIV prevention medication (Emtricitabine + Tenofovir) for people at sexual risk, including MSM, transgender individuals, sex workers, and partners of HIV-positive individuals, with quarterly check-ups and monitoring.
• Travel Clinic Outpatient clinic serving approximately 24,000 travelers annually with pre- and post-travel consultations, vaccinations, and laboratory testing for tropical infections including malaria, dengue, chikungunya, zika, and West Nile fever.
• HIV/AIDS Clinic Outpatient clinic specializing in the diagnosis, treatment and care of HIV/AIDS and other sexually transmitted infections.
• Chemsex Centre Interdisciplinary expert centre providing specialized care for people who experience physical, mental or social problems related to drug use in sexual contexts, offering low-threshold access to support.
• Master's Programmes in Tropical Medicine and Global Health Master's programmes in tropical medicine, international public health and Global One Health for professionals worldwide.
• Postgraduate Certificate Programmes Postgraduate certificate programmes in tropical medicine and international public health.
• Expert Short Courses in Global Health Short courses in tropical medicine, international public health and Global One Health for professionals worldwide.
• Reference Laboratories for Tropical and Infectious Diseases Reference laboratories providing specialized diagnostic services and quality control for tropical and infectious diseases for partner institutions.
• Clinical Trial Site Operations Clinical trial infrastructure conducting clinical studies on emerging infectious diseases, vaccines, and therapeutics, including adaptive platform trial design.
• Transmission Podcast Award-winning podcast sharing stories from ITM researchers and physicians battling diseases, with seasons on outbreaks, health systems, and elimination efforts.

Quantifiable outcome

• EBO-BOOST study enrolled 624 participants to study optimal Ebola booster vaccination strategies
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)coreStrategic or Co-development Partner · 8 July 2026KCCR at Kwame Nkrumah University of Science and Technology in Ghana leads community engagement work package for PARTNERS trial, supporting local teams to build trust with affected communities.
• Institut National pour la Recherche Biomédicale (INRB)coreStrategic or Co-development Partner · 2 July 2026INRB is ITM's long-term partner in the Democratic Republic of Congo for Ebola research and outbreak response. Together they coordinate the PARTNERS clinical trial for Bundibugyo Ebola treatments and the EBO-BOOST study on Ebola booster vaccinations.
• University of OxfordcoreStrategic or Co-development Partner · 2 July 2026Oxford University collaborates with ITM on clinical trials for Ebola treatments, including the PARTNERS trial testing MBP134 and remdesivir against Bundibugyo virus.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 2 July 2026WHO sponsors and coordinates international clinical trials including the PARTNERS trial, working with ITM and other partners to evaluate treatments for Bundibugyo Ebola.
• Africa CDCcoreStrategic or Co-development Partner · 2 July 2026Africa CDC supports the PARTNERS clinical trial and outbreak response efforts with ITM in the Democratic Republic of Congo.
• Gilead SciencesminorOthers · 2 July 2026Gilead Sciences donated remdesivir for the PARTNERS clinical trial testing treatments for Bundibugyo Ebola virus disease.
• Mapp BiopharmaceuticalminorOthers · 2 July 2026Mapp Biopharmaceutical's experimental antibody treatment MBP134 is being tested in the PARTNERS clinical trial for Bundibugyo Ebola.
• ALIMA (The Alliance for International Medical Action)coreStrategic or Co-development Partner · 2 July 2026ALIMA collaborates in the PARTNERS clinical trial for Bundibugyo Ebola treatments in DRC.
• Médecins Sans Frontières (MSF)coreStrategic or Co-development Partner · 2 July 2026MSF supports the PARTNERS clinical trial and outbreak response efforts in the Democratic Republic of Congo.
• Seven Hospitals Across BelgiumcoreStrategic or Co-development Partner · 12 March 2026Collaborating hospitals for be-IMPACT project monitoring drug-resistant malaria parasites among returning travelers.
• Institut de Recherche pour le Développement (IRD)coreStrategic or Co-development Partner · 1 October 2023French research institute partnering on the EBO-BOOST study for Ebola booster vaccination research.
• Programme Elargi de Vaccination (PEV)coreStrategic or Co-development Partner · 1 October 2023DRC's expanded vaccination program collaborates on Ebola vaccine research and trial implementation.
• Partner Institutions in Africa, Asia, and Latin AmericacoreStrategic or Co-development PartnerITM works with numerous partners across three continents on institutional capacity sharing and collaboration in tropical medicine research and education.
• Mahidol UniversitycoreStrategic or Co-development PartnerLeading mRNA vivax malaria vaccine development project with Chulalongkorn University and Ehime University, funded by GHIT Fund (USD 4.1 million).
• Barcelona Institute for Global HealthcoreStrategic or Co-development PartnerPartner in GHIT Fund projects targeting malaria, tuberculosis, and neglected tropical diseases R&D.
• EisaiminorStrategic or Co-development PartnerPartner in Chagas disease drug development project (USD 1.1 million) as part of GHIT Fund portfolio.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Pasteur Institute: Paris-based, internationally renowned biomedical research organisation covering infectious diseases, immunology, and tropical pathogens at much greater scale. Overlaps on outbreak response, virology, and tropical disease diagnostics.
• U.S. Centers for Disease Control and Prevention (CDC): U.S. federal public health agency operating reference labs, outbreak response, and global health programmes at vastly greater scale. Overlaps with ITM on tropical disease diagnostics, outbreak investigation, and international capacity building.

Direct peers

• Liverpool School of Tropical Medicine: UK institution founded in 1898 dedicated to tropical medicine research and postgraduate teaching. Overlaps with ITM on clinical trial capacity, vector-borne disease research, and global health education.
• London School of Hygiene & Tropical Medicine: London-based research and postgraduate teaching institution focused on public and global health, with directly comparable master's programmes, research output, and tropical disease expertise. Often benchmarked alongside ITM as one of Europe's two flagship tropical medicine schools.
• Bernhard Nocht Institute for Tropical Medicine: Hamburg-based German tropical medicine institute with comparable BSL-3 laboratory, clinical tropical medicine, and research portfolio on emerging infections, malaria, and haemorrhagic fevers.
• Swiss Tropical and Public Health Institute (Swiss TPH): Basel-based institute combining tropical medicine research, education, and clinical services with strong ties to international funders. Closely comparable on the research-education-clinical mix and European tropical disease focus.
• Mahidol University Faculty of Tropical Medicine: Bangkok-based tropical medicine faculty partnering with ITM on the mRNA vivax malaria vaccine (GHIT-funded). Closely comparable research and training portfolio across tropical infectious diseases in Asia.
• Barcelona Institute for Global Health (ISGlobal): Spain-based global health research and translation institute explicitly partnering with ITM on GHIT-funded malaria, TB, and neglected tropical disease projects. Comparable mission, tropical disease focus, and international partnership model.

Others

• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI funds ITM's EBO-BOOST study and related vaccine programmes; not a peer institution but a core funder-collaborator whose priorities directly shape ITM's trial pipeline and revenue trajectory.

Emerging players

• Epicentre (MSF): Field epidemiology and clinical research arm of Médecins Sans Frontières, co-implementing the PARTNERS trial with ITM. Comparable as an operational research partner in outbreak and tropical disease settings in Africa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ITMantwerp
• YouTubeyoutube.com/@InstituteofTropicalMedicine
• Facebookfacebook.com/ITGITMANTWERP
• LinkedInlinkedin.com/school/institute-of-tropical-medicine
• Instagraminstagram.com/itmantwerp

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute Of Tropical Medicine